558 related articles for article (PubMed ID: 28143835)
1. Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy.
Fajardo CA; Guedan S; Rojas LA; Moreno R; Arias-Badia M; de Sostoa J; June CH; Alemany R
Cancer Res; 2017 Apr; 77(8):2052-2063. PubMed ID: 28143835
[TBL] [Abstract][Full Text] [Related]
2. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
[TBL] [Abstract][Full Text] [Related]
3. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
[TBL] [Abstract][Full Text] [Related]
4. Enhanced antitumor efficacy of an oncolytic adenovirus armed with an EGFR-targeted BiTE using menstrual blood-derived mesenchymal stem cells as carriers.
Barlabé P; Sostoa J; Fajardo CA; Alemany R; Moreno R
Cancer Gene Ther; 2020 May; 27(5):383-388. PubMed ID: 31204390
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas.
Arnone CM; Polito VA; Mastronuzzi A; Carai A; Diomedi FC; Antonucci L; Petrilli LL; Vinci M; Ferrari F; Salviato E; Scarsella M; De Stefanis C; Weber G; Quintarelli C; De Angelis B; Brenner MK; Gottschalk S; Hoyos V; Locatelli F; Caruana I; Del Bufalo F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963009
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
[TBL] [Abstract][Full Text] [Related]
7. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer.
Wang Q; Ma X; Wu H; Zhao C; Chen J; Li R; Yan S; Li Y; Zhang Q; Song K; Yuan C; Kong B
Oncoimmunology; 2022; 11(1):2096362. PubMed ID: 35800156
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.
Freedman JD; Hagel J; Scott EM; Psallidas I; Gupta A; Spiers L; Miller P; Kanellakis N; Ashfield R; Fisher KD; Duffy MR; Seymour LW
EMBO Mol Med; 2017 Aug; 9(8):1067-1087. PubMed ID: 28634161
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
[TBL] [Abstract][Full Text] [Related]
12. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.
Yu F; Wang X; Guo ZS; Bartlett DL; Gottschalk SM; Song XT
Mol Ther; 2014 Jan; 22(1):102-11. PubMed ID: 24135899
[TBL] [Abstract][Full Text] [Related]
13. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.
Fernández-Ulibarri I; Hammer K; Arndt MA; Kaufmann JK; Dorer D; Engelhardt S; Kontermann RE; Hess J; Allgayer H; Krauss J; Nettelbeck DM
Int J Cancer; 2015 May; 136(9):2228-40. PubMed ID: 25303768
[TBL] [Abstract][Full Text] [Related]
14. Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.
Speck T; Heidbuechel JPW; Veinalde R; Jaeger D; von Kalle C; Ball CR; Ungerechts G; Engeland CE
Clin Cancer Res; 2018 May; 24(9):2128-2137. PubMed ID: 29437789
[No Abstract] [Full Text] [Related]
15. Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers.
Santos J; Heiniö C; Quixabeira D; Zafar S; Clubb J; Pakola S; Cervera-Carrascon V; Havunen R; Kanerva A; Hemminki A
Cells; 2021 Apr; 10(5):. PubMed ID: 33922052
[TBL] [Abstract][Full Text] [Related]
16. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
Kanaya N; Kuroda S; Kakiuchi Y; Kumon K; Tsumura T; Hashimoto M; Morihiro T; Kubota T; Aoyama K; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Mizuguchi H; Urata Y; Fujiwara T
Mol Ther; 2020 Mar; 28(3):794-804. PubMed ID: 31991110
[TBL] [Abstract][Full Text] [Related]
17. Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors.
Tanoue K; Rosewell Shaw A; Watanabe N; Porter C; Rana B; Gottschalk S; Brenner M; Suzuki M
Cancer Res; 2017 Apr; 77(8):2040-2051. PubMed ID: 28235763
[TBL] [Abstract][Full Text] [Related]
18. CCL21/IL21-armed oncolytic adenovirus enhances antitumor activity against TERT-positive tumor cells.
Li Y; Li YF; Si CZ; Zhu YH; Jin Y; Zhu TT; Liu MY; Liu GY
Virus Res; 2016 Jul; 220():172-8. PubMed ID: 27157859
[TBL] [Abstract][Full Text] [Related]
19. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
[TBL] [Abstract][Full Text] [Related]
20. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
Lee YS; Kim JH; Choi KJ; Choi IK; Kim H; Cho S; Cho BC; Yun CO
Clin Cancer Res; 2006 Oct; 12(19):5859-68. PubMed ID: 17020994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
